ライフサイエンスコーパス: recipient

1 transplant recipient, and 1 lung transplant recipient.

2 o myelodysplastic syndrome in both donor and recipient.

3 inst malignant and nonmalignant cells of the recipient.

4 megalovirus retinitis in a kidney transplant recipient.

5 ompared between indigenous and nonindigenous recipients.

6 ALL, relapsed ALL, and stem cell transplant recipients.

7 ely occurs in kidney and pancreas transplant recipients.

8 thy (CAV) in pediatric heart transplant (HT) recipients.

9 in regulating lung injury in lung transplant recipients.

10 utcome as compared to liver transplant (LTx) recipients.

11 of COVID-19 infection among organ transplant recipients.

12 = 0.007; OR, 7.93; 95% CI, 1.75-35.69) in LT recipients.

13 organ and hematopoietic stem cell transplant recipients.

14 nities to improve the outcomes of transplant recipients.

15 tive study included 282 HCC liver transplant recipients.

16 ion in a clinical trial of kidney transplant recipients.

17 ared with matched cardiomyopathy-related HTx recipients.

18 d in 2055 biopsies from 775 renal transplant recipients.

19 Data were analyzed for 25 140 recipients.

20 s rare, occurring in 0.18% of all transplant recipients.

21 is for 100 days in 205 D+R- liver transplant recipients.

22 k factor was substance abuse in 1941 (12.6%) recipients.

23 pproach may be feasible and safe in selected recipients.

24 ity by preventing or delaying CS-CMVi in HCT recipients.

25 individualize counseling and management for recipients.

26 opportunistic infection in kidney transplant recipients.

27 crolimus-induced hyperglycemia in transplant recipients.

28 monitored ART suppressed HIV-positive organ recipients.

29 eic hematopoietic cell transplant (allo-HCT) recipients.

30 f islet allograft survival in allosensitized recipients.

31 2) were similar between pre-KAS and post-KAS recipients.

32 igestive tract pathogens in liver transplant recipients.

33 ared to prophylaxis in D+R- liver transplant recipients.

34 rejection on protocol biopsy in pediatric HT recipients.

35 kidneys are rejected within a week in DBA/2J recipients.

36 alth interventions in solid organ transplant recipients.

37 afts were transplanted into MHC-heterozygous recipients.

38 nd possibly more effective management of HCT recipients.

39 PTp-SP efficacy and enhanced morbidity in SP recipients.

40 recipients to immunocompetent, nontransplant recipients.

41 or transferred to diabetic and non-diabetic recipients.

42 increasing hepatic complications in HCV+ KT recipients.

43 ain, this association was not seen with male recipients.

44 re, scattering over 12 months across all SOT recipients.

45 individuals compared with late-recovered HCT recipients.

46 ors, deceased donor families, and transplant recipients.

47 rmore, we included studies of nulliparous KT recipients.

48 using the Scientific Registry of Transplant Recipients.

49 of mortality in kidney and liver transplant recipients.

50 significantly higher in Triplex than placebo recipients.

51 al transplant recipients, 1 liver transplant recipient, 1 heart transplant recipient, and 1 lung tran

52 dalities, and outcomes of 7 renal transplant recipients, 1 liver transplant recipient, 1 heart transp

53 Among 308 CMV seronegative recipients, 168 CMV high-risk and 203 belatacept-treated

54 Ig survived indefinitely, whereas 80% of old recipients (18 months) had lost their graft after 100 da

55 s from the Scientific Registry of Transplant Recipients (2000-2019).

56 Whole blood recipients (2016-2019) were compared to a propensity-mat

57 Among 1182 adult SOT recipients, 28 (2.4%), 77 (6.5%), 65 (5.5%), and 22 (1.9

58 DGF was diagnosed in 4/6 (67%) G1 recipients, 3/3 (100%) G3 recipients, and 0/6 (0%) G2 re

59 pients, BPAR rates were higher in indigenous recipients (42 versus 74 episodes/100 recipients, P < 0.

60 Of 43,192 LT recipients, 43,026 (99.6%) were US citizens/residents an

61 idence of acute liver injury was lower in LT recipients (47.5% vs. 34.6%; P = 0.037).

62 Among 2153 SOT (65%) and HCT (35%) recipients, 634 (29%) reported any antibiotic allergy an

63 episodes of CDI were diagnosed among 79 SOT recipients (7.3%), and exposure to PPIs (OR 2.4, 95% CI

64 sponses were obtained from 62 of 87 eligible recipients (71.2% response rate).

65 We assessed 100 adult HCT recipients a median of 9.3 years (range: 1.7-40) after t

66 atedness between the actor (brain fluke) and recipients (abdomen flukes) enables kin selection of the

67 Survival also improved in plasma recipients (adjusted hazard ratio (HR), 0.34; 95% CI, 0.

68 ere identified in a higher proportion of HCT recipients after replacing conventional stool testing wi

69 andom effect) to evaluate the association of recipient age and patient survival.

70 ariables impacting outcome include donor and recipient age, CC, non-DBD donor and reduced graft size.

71 s), ST2 remained associated with NRM only in recipients age 10 years or younger (HR, 4.82; 95% CI, 1.

72 ance maintenance; and (b) the possibility of recipient allo-sensitization by CMV-mediated disruption

73 2) was performed using the variables such as recipient and donor age, indication of LT.

74 The parameter ICG Ingress reflects recipient and procedure characteristics and is able to p

75 TAT-4 phosphorylation in 29 HCV-infected LTx-recipients and 17 HCV-infected patients during DAA-treat

76 ) comprising 4 transgender kidney transplant recipients and 2 transgender living donors was construct

77 Donor-origin mutant clones engrafted in recipients and expanded during the first 100 days after

78 and cardiothoracic transplant candidates and recipients and explore potential interventions to addres

79 n cause severe clinical disease in allograft recipients and infants infected in utero Virus-neutraliz

80 tes that pregnancy is contraindicated in all recipients and the majority of programs have no center-s

81 eficial for vascularized composite allograft recipients and victims of traumatic major limb amputatio

82 verse events were reported by 44% of vaccine recipients and were transient and mild or moderate in in

83 ver transplant recipient, 1 heart transplant recipient, and 1 lung transplant recipient.

84 ed in 4/6 (67%) G1 recipients, 3/3 (100%) G3 recipients, and 0/6 (0%) G2 recipients (P = .008).

85 hogens in heart, lung, and kidney transplant recipients, and as digestive tract pathogens in liver tr

86 n long-term potentiation (LTP) in transplant recipients, and LTP impairment in TRANSWT mice was IL-1

87 d that pregnancy should be avoided in all HT recipients, and only 43% (n=52) reported that their cent

88 played a minor role as IDSA leaders, awards recipients, and presenters at the national meeting.

89 e need for special requirements for selected recipients, and the necessity for traceability of blood

90 single) lung recipients, and those with fewer than four (vs.

91 to protect seronegative women and transplant recipients, and we should know soon whether they can pre

92 e) and of SR-uPA(+/0) bone marrow transplant recipients, and we used bioinformatic tools to evaluate

93 similar in TAK-003 (4.0%) and placebo (4.8%) recipients, and were consistent with expected medical di

94 c factors were increased in DM versus non-DM recipients, and, relevantly, metformin use was associate

95 ctivity, impaired learning and memory in the recipient animals.

96 Solid organ transplant recipients are at risk for potentially life-threatening

97 sociated with receiving aid is countered and recipients are empowered, both in culturally resonant wa

98 ed T(regs) in T1D and solid-organ transplant recipients are limited by poor T(reg) engraftment withou

99 eic hematopoietic cell transplant (allo-HCT) recipients, as a result of intestinal translocation duri

100 IRI, we treated syngeneic cardiac transplant recipients at 1-hour posttransplant with Anakinra, a US

101 Kidney transplant recipients at high risk for infections might benefit fro

102 prophylaxis in solid organ transplant (SOT) recipients at increased risk.

103 HLA antibodies identifies cardiac transplant recipients at risk of rejection.

104 irs at the time of transplantation, and from recipients at several timepoints up to 3 years after tra

105 tive sera obtained from 12 cardiac allograft recipients at the time of biopsy-proven rejection.

106 ed genes, silencing recessive alleles if the recipient bacterium already carries a wild-type copy of

107 , we studied 110,019 adult deceased-donor KT recipients between 2005 and 2017.

108 logic phenotyping from 224 kidney transplant recipients between 2011 and 2017.

109 vival of life-supporting pig heart xenograft recipients beyond 90 days was recently reported using ge

110 Compared with nonindigenous recipients, BPAR rates were higher in indigenous recipie

111 es sterile immunity to P. falciparum in some recipients, but a single 45 mg dose of primaquine postex

112 ty among hematopoietic cell transplant (HCT) recipients, but the etiology is often not identified.

113 tegy via matching deceased kidney donors and recipients by CMV serostatus.

114 ntly more RIFs were found in (177)Lu-DOTATOC recipients by comparison, despite lower dose rates and b

115 Although it is now clear that VCA recipients can develop donor-specific antibodies, conclu

116 rgical ileostomy after ITx reveals that most recipients can undergo successful ileostomy formation/ta

117 jection was associated with proliferation of recipient CD8 T effector cells in the periphery and live

118 NA cargo of extracellular vesicles can alter recipient cell gene expression and function.

119 is stably retained in mtDNA-deficient (rho0) recipient cells following uridine-free selection, althou

120 s documented multiple biochemical changes in recipient cells shortly after mtDNA transfer, but the lo

121 induced canonical Wnt signaling in infected recipient cells while simultaneously inhibiting HIV tran

122 vesicles, and this changes the phenotype of recipient cells.

123 rried miRNA in modulating gene expression in recipient cells.

124 sferring their content following uptake into recipient cells.

125 bability of treatment weighting on donor and recipient characteristics, we found that 1-, 5-, and 10-

126 survival models and tested interactions with recipient characteristics.

127 powerment" narrative significantly motivated recipients' choice to build skills and reduced stigma.

128 graft failure independent of both donor and recipient clinical characteristics included interstitial

129 emia in high-risk donor CMV-seropositive and recipient CMV-seronegative (D+R-) liver transplant recip

130 impacts of native and invasive predators on recipient communities.

131 ence of systemic immunosuppression, diabetic recipients containing PVPON/TA-encapsulated islets maint

132 After transfer into wild-type recipient, Cosmc-null B cells fail to home to lymph node

133 rovide contemporary data on sex mismatch for recipient counseling and reassurance with regards to equ

134 nding by donor for the 20 largest donors, by recipient-country income group, and by recipient for the

135 We applied Scientific Registry of Transplant Recipients data from 2011 to 2016 toward the Liver Simul

136 Using Scientific Registry of Transplant Recipients data, we compared data on observed waitlist r

137 The Scientific Registry of Transplant Recipients database was reviewed to identify adult liver

138 ell-driven colitis in both Cre(+) and Cre(-) recipients, demonstrating that IRF4 expression by cDC is

139 Recipients developed CMV viremia during the first month

140 We present 21 SOT recipients diagnosed with COVID-19 between January 1, 20

141 However, these changes affected HS recipients differently based on cPRA.

142 in high-immunological risk kidney transplant recipients due to a perceived increased risk of rejectio

143 Compared with non-en bloc recipients, en bloc recipients had lower 1-y graft survi

144 Two cohorts of kidney transplant recipients enrolled in the Deterioration of Kidney Allog

145 lex, in which the forming layers-the thalamo-recipient entopallium (E), an overlaying nidopallial str

146 ACS events in TAVR recipients exhibited specific characteristics (ACS prese

147 on cases, we observe that the viruses in the recipient ferrets are of the same genotype as the viruse

148 Mean recipient follow-up was 6.3 years, during which 287 deat

149 of 30 HCV-viremic kidneys into HCV-negative recipients, followed by early initiation of an 8-week re

150 s, by recipient-country income group, and by recipient for the 16 countries with the greatest RMNCH n

151 d from the Scientific Registry of Transplant Recipients for adults listed and removed from the liver

152 esults in gut microbiota engraftment in most recipients for at least 12 weeks.

153 Testing donors and recipients for HHV-8 is currently challenging with no va

154 use of limited techniques for distinguishing recipient from donor cells.

155 reviewed to identify adult liver transplant recipients from 2002 through 2016 with MELD score >=40 a

156 ively collected national registry data on LT recipients from 2002 to 2017 with ALD as the primary lis

157 We studied 6214 adult SLK recipients from March 2002 to February 2017 using the Sc

158 adult (age > 17) solitary kidney transplant recipients from the Scientific Registry of Transplant Re

159 NB n = 29; SAB n = 26) and 225 nontransplant recipients (GNB n = 114; SAB n = 111) were included for

160 Fifty-five transplant recipients (GNB n = 29; SAB n = 26) and 225 nontransplan

161 In KTA recipients, graft quality correlates directly to graft s

162 Conversely, nonpreferred recipients had a 41% increased mortality risk (HR: 1.171

163 All but 2 recipients had a congenital absence of the uterus.

164 In phase 1, 50% of recipients had a technically successful uterus transplan

165 e randomized, 17 dipyridamole and 18 placebo recipients had baseline and week 12 data available for a

166 ompared with non-en bloc recipients, en bloc recipients had lower 1-y graft survival (78.9% versus 88

167 eing associated with reduced graft survival, recipients had lower mortality rates than those remainin

168 Compared to SPK,P+, DD-KA, or LD-KA recipients had significantly higher risk of kidney allog

169 hat cause important infections in transplant recipients has been the standard of care for years, impo

170 Elderly organ transplant recipients have remained underrepresented in clinical tr

171 t and patient survival among HIV-infected LT recipients have shown improvement over time.

172 h-dose novel OPV2-c2 despite monovalent OPV2 recipients having higher baseline immunity.

173 esity among pediatric solid-organ transplant recipients (heart, lung, liver, kidney, multiorgan) at T

174 Transfection of eight upregulated LTRs into recipient human cells in culture showed robust and heter

175 heir interaction with allograft-infiltrating recipient immune cells and potential therapeutic approac

176 The per protocol analysis identified LT recipients in group B with concomitant early CNI minimiz

177 ent CMV-seronegative (D+R-) liver transplant recipients in the current era are incompletely defined.

178 Standard-of-care immunosuppression in the recipients in the RGT resulted in a 12% BCAR rate (expec

179 sitization in previously tolerant transplant recipients in whom tolerance maintenance is disrupted by

180 formation about outcomes (i.e., identity and recipient) in the service of promoting attention in some

181 cases of COVID-19 in solid organ transplant recipients including recipients of kidney, liver, lung,

182 evere), compared with 15 (88%) of 17 placebo recipients (including two severe).

183 postoperative care of solid organ transplant recipients is evolving.

184 we studied Scientific Registry of Transplant Recipients kidney offer data for 3642 pediatric (age <18

185 ffects on the evolution of kidney transplant recipients (KTRs).

186 Allografts were rapidly infiltrated by recipient leukocytes, which recapitulated the liver myel

187 PEA from the donor PE lipid substrate to the recipient lipid A molecule by a putative 'ping-pong' tra

188 f morbidity and mortality in lung transplant recipients (LTRs).

189 ith HHV-8 infection risk could be useful for recipient management.

190 e antigen antibodies (Anti-HLA Ab) for donor-recipient matching and patient risk stratification in re

191 information can be used to facilitate donor/recipient matching and to improve informed consent.

192 en bloc with 581 non-en bloc deceased donor recipients (matching variables: transplant age, gender,

193 such modular structure, containing auditory-recipient matrix regions and GABA-rich modules that are

194 D-MELD (donor age x recipients' MELD) was associated with postoperative mort

195 es were xenotransplanted subcutaneously into recipient mice for 4 weeks.

196 of allogeneic skin grafts in young RAG2(-/-) recipient mice.

197 Among recipients, more cPRA 98%-99.9% and 99.9%+ recipients un

198 ME, thus improving mitochondria activity in recipient MSC.

199 erated by thalamic astrocytes and not retino-recipient neurons.

200 conventional RGCs (non-ipRGCs) target ipRGC-recipient nuclei to influence subconscious visual behavi

201 Recipient obesity was defined as body mass index (BMI) >

202 virion assays were 3- to 9-fold higher among recipients of 2-dose EBOV GP with adjuvant, compared wit

203 opulation Immunocompromised patients who are recipients of a solid organ or hematopoietic stem cell t

204 c analyses of fecal and blood specimens from recipients of allogeneic hematopoietic cell transplant.

205 Recipients of an HLA-DR1 donor also have an impaired car

206 Forty type 1 diabetes recipients of intraportal islet cell grafts under antith

207 solid organ transplant recipients including recipients of kidney, liver, lung, and heart transplants

208 Thus, recipients of LD, DCD, and AKI kidneys were studied to p

209 ifference in 1-year overall survival between recipients of NMP versus COLD livers.

210 areness of the risk of posttransplant KS for recipients of organs from donors with HHV-8 infection ri

211 Recipients of organs with Ureaplasma spp who received em

212 , completely rescued in irradiated wild-type recipients of PDIA6-deficient bone marrow cells, both in

213 course and management of a liver transplant recipient on hemodialysis, who presented with COVID-19 p

214 -infected adult solid organ transplant (SOT) recipients on antiretroviral therapy.

215 creased risk of 1-y graft loss among en bloc recipients only appeared in the oldest era.

216 Recipient, operative, and donor characteristics during C

217 Organ transplant recipients (OTRs) are at increased risk of cutaneous mal

218 survival and function in >90% of allogeneic recipients over a 100-d observation period.

219 s, 3/3 (100%) G3 recipients, and 0/6 (0%) G2 recipients (P = .008).

220 genous recipients (42 versus 74 episodes/100 recipients, P < 0.01), with an excess of antibody-mediat

221 mononuclear cells were collected from donor-recipient pairs at the time of transplantation, and from

222 maximizing the dispersal of refugees in the recipient population contributes to impede the spread of

223 Compared with pre-KAS recipients, post-KAS recipients were allocated kidneys w

224 C57BL/6 (H2K(b), I-A(b)) recipients pre-treated with BALB/c MDSCs were transplant

225 was used to confirm viral replication in SOT-recipients presenting with clinical evidence of infectio

226 chaperone, binding and transferring iron to recipient proteins in mammalian cells.

227 Vaccine recipients received ALVAC-HIV (vCP2438) alone at months

228 Eighteen recipients received uteri from living donors and 2 from

229 er compared to those carried by non-diabetic recipients, regardless hyperglycemia status of oocyte do

230 DWF and DC-GF in kidney transplant recipients represent differing clinical phenotypes occur

231 (95% CI: 52.2%-68.4%) in 1-drop and 2-drops recipients, respectively.

232 DMOG treatment of allogeneic recipients resulted in increased hypoxia-inducible facto

233 altruistically, or in advance of a potential recipient's transplant, and to receive a voucher that ca

234 sociated with patient survival in indigenous recipients should be considered a priority.

235 ver $48 million from NIH was awarded to JPIA recipients since 2008, representing a 147-fold return on

236 2010-2018 Scientific Registry for Transplant Recipients (SRTR) data to identify 92 081 adult kidney t

237 e strictly "necessary" items to lower-income recipients (study 8), even if such items are objectively

238 visual rehabilitation for retinal prostheses recipients, such the CAREN system, are feasible and may

239 t is important that kidneys are allocated to recipients that are able to maximize their benefit from

240 the risk of cancer recurrence in transplant recipients, the goal of the AST-sponsored conference and

241 imultaneous pancreas-kidney (SPK) transplant recipients, the majority of complications described in t

242 hemokine and cytokine response in transplant recipients to immunocompetent, nontransplant recipients.

243 which we randomized stable kidney transplant recipients to Tac withdrawal or maintenance of standard

244 trait, which facilitates transmission of the recipients to the final host.

245 her demonstrate that late graft rejection in recipients treated with this regimen is associated with

246 g recipients, more cPRA 98%-99.9% and 99.9%+ recipients underwent DDKT (96.2% in Era 3% vs 59.1% in E

247 Overall 29.2% of KT recipients underwent ESW.

248 easured in 32 of 36 viremic pediatric kidney recipients using intracellular cytokine staining and flo

249 SNVs in the scRNA-seq data set distinguished recipient versus donor origin for all 81,139 cells exami

250 The mean 12-month eGFR for AKI kidney recipients was lower, but differences were not clinicall

251 of these therapies in solid organ transplant recipients was not assessed in clinical trials.

252 From 1988 consecutive renal transplant recipients, we analyzed 179 patients undergoing retransp

253 m, and the Scientific Registry of Transplant Recipients, we compared population-level characteristics

254 Using the Scientific Registry of Transplant Recipients, we studied 110,019 adult deceased-donor KT r

255 Compared with pre-KAS recipients, post-KAS recipients were allocated kidneys with lower Kidney Dono

256 Ninety-two percent of the 418 primary recipients were children, and 47% were accepted on the f

257 Spleens and allografts from C57BL/6 recipients were harvested for immune phenotyping, transc

258 CMV seronegative kTx recipients were included.

259 Recipients were injected daily with 5 mg/kg cyclosporine

260 optively transferred TEa cells in skin-graft recipients were not exhausted.

261 Overall, 394 KT recipients were randomized to receive immediate (N = 197

262 xpression datasets of solid organ transplant recipients were retrieved from the Gene Expression Omnib

263 However, fetuses carried by diabetic recipients were smaller compared to those carried by non

264 t uninfected donors to transplant uninfected recipients while maintaining safety for health care syst

265 ences that change for in-group and out-group recipients, while not-groupy participants' preferences d

266 esent a dual-organ (heart/kidney) transplant recipient who was found to have COVID-19 and, despite th

267 , higher platelet counts were observed among recipients who achieved full (>95%) vs low-level (5%-49%

268 onses, did not correlate with viral loads in recipients who became infected, cross-reactivity did app

269 Recipients who developed DSA had significantly lower qua

270 included consecutive adult liver transplant recipients who had their surgery between July 2008 and D

271 a retrospective chart review of pediatric HT recipients who had undergone HT between January 2010 and

272 In contrast, HCV+ recipients who received ATG were at lower risk of acute

273 tive study of stem cell and organ transplant recipients who received letermovir for the treatment of

274 4 and IL-4CD4 cells; P = 0.0001) compared to recipients who remained DSA-negative over the first-year

275 s isolated and orthotopically sutured to the recipient, whose bladder above the ureteral opening leve

276 have delivered 1 or 2 babies, and the fifth recipient with a technical success is >30 weeks pregnant

277 the first case of CG in a kidney transplant recipient with kidney disease of unknown cause.

278 ~9 months to a 57-year-old kidney transplant recipient with metastatic cutaneous squamous cell carcin

279 ntrol or cohort design studies comprising KT recipients with a diagnosis of IA, defined according to

280 of death 12 months after transplantation in recipients with a kidney from donors >=80 years was 0.54

281 Four recipients with a technical success in phase 1 have deli

282 Three-year cumulative graft survival in LT recipients with and without HIV infection was 64.4% and

283 Among 3146 SLK recipients with CKD, nearly two-thirds were 50-64 years

284 loss or death occurred in about one third of recipients with DDD, with higher rates associated with m

285 Recipients with DGF had lower odds of ESW (aOR=(0.60)0.6

286 to the end of follow-up, contrasting vaccine recipients with different values of the immune response

287 emic heart transplantation into HCV-negative recipients with HCV treatment are good.

288 eased mortality (aHR=(0.86)0.89(0.93)) among recipients with IGF.

289 Data from adult LT recipients with laboratory confirmed SARS-CoV2 infection

290 ed survival and clinical outcomes in elderly recipients with low immunological risk according to thei

291 polyfunctionality scores relative to vaccine recipients with no late boost (all adjusted p<0.05, exce

292 In addition, 3 of 5 recipients with POD after a first cycle who received EBV

293 ed HLA antibodies (DSA-M) in renal allograft recipients with pretransplant donor-specific HLA antibod

294 itial experience with solid organ transplant recipients with SARS-CoV-2 infection at two centers duri

295 Among CMV-seronegative liver transplant recipients with seropositive donors, the use of preempti

296 quate future liver remnant in donor, GRWR in recipient), with up to 20% macrovesicular steatosis, doe

297 Recipients within the IL-10(+) cluster had a significant

298 s and seroprotection rates of allogeneic HCT recipients years after different schedules of vaccinatio

299 Kidney recipients, younger children, those overweight at transp

300 County Health Ranking data using transplant recipient zip code, and nationwide County Health Ranking